SCHEMBL14036104

SCHEMBL14036104

CNNc1ncnc2[nH]ncc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 2/20 0.73
ALDH1A1 P00352 1/20 0.58
MKNK1 Q9BUB5 3/20 0.55
MAPK1 P28482 2/20 0.55
HPGDS O60760 1/20 0.54
CYP1A2 P05177 3/20 0.54
RET P07949 1/20 0.53
PI4KA P42356 1/20 0.53
XDH P47989 1/20 0.53
LRRK2 Q5S007 1/20 0.53
PI4K2B Q8TCG2 1/20 0.53
PI4K2A Q9BTU6 1/20 0.53
PI4KB Q9UBF8 1/20 0.53
CHEK1 O14757 1/20 0.51
AURKA O14965 1/20 0.51
CCNT1 O60563 1/20 0.51
CCNA2 P20248 1/20 0.51
CDK2 P24941 1/20 0.51
CDK9 P50750 1/20 0.51
CCNA1 P78396 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10094590 0.85 PDPK1 (1.00) PDPK1ALDH1A1MKNK1MAPK1HPGDS
SCHEMBL14827602 0.76 PDPK1 (0.66) PDPK1ALDH1A1MKNK1MAPK1HPGDS
SCHEMBL10094121 0.76 PDPK1 (0.66) PDPK1ALDH1A1MKNK1MAPK1HPGDS
SCHEMBL30763272 0.74 XDH (0.63) PDPK1ALDH1A1MKNK1MAPK1HPGDS
SCHEMBL28839743 0.74 XDH (0.63) PDPK1ALDH1A1MKNK1MAPK1HPGDS
SCHEMBL6471191 0.74 PDPK1 (0.62) PDPK1ALDH1A1MKNK1MAPK1HPGDS
SCHEMBL13369827 0.73 PDPK1 (0.61) PDPK1ALDH1A1MKNK1MAPK1HPGDS
SCHEMBL2619226 0.72 RET (0.61) PDPK1ALDH1A1MKNK1MAPK1HPGDS
SCHEMBL10836838 0.71 ALDH1A1 (0.73) PDPK1ALDH1A1MKNK1MAPK1HPGDS
SCHEMBL14036208 0.71 HPGDS (0.68) PDPK1ALDH1A1MAPK1HPGDSCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452893-B2 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists MERCK & CO., INC. (US) 2008-11-18 US disclosed
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients MERCK & CO., INC. (US) 2007-02-15 US disclosed
EP-1656379-B1 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2007-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients GRIN2B, GRIN3A, GRIN2A PDPK1 846/4885ALDH1A1 636/4885MKNK1 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.